Clinical Trials Logo

Hepatic Steatosis clinical trials

View clinical trials related to Hepatic Steatosis.

Filter by:

NCT ID: NCT05124847 Completed - Metabolic Syndrome Clinical Trials

TREating Pediatric Obesity

TREPO
Start date: September 27, 2021
Phase: N/A
Study type: Interventional

The main aim of the study is to collect preliminary information on the feasibility and efficacy of a time restricted eating intervention in Spanish children and adolescents with obesity and metabolic comorbidities. Two 8-week interventions will performed in a randomized crossover controlled design: a) reduction of the habitual eating window; b) standard care. Different measurements of body composition and cardiometabolic health markers will be performed along those weeks.

NCT ID: NCT04898621 Completed - Hepatic Steatosis Clinical Trials

Dietary Fructose on Microbiota and Hepatosteatosis

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The consumption of sugar-sweetened beverages (SSB) has increased steadily over the past decades, resulting in the dramatic increase of fructose intake as it is one of the main ingredients of artificial sweeteners. Recently, large epidemiological studies have documented the association between a high-fructose-diet and hepatic steatosis, and other metabolic disorders. So it is interesting for scientists to explore the underlying mechanism. This study aims to investigate the effect of dietary fructose and gut microbiota and the hepatosteatosis in healthy men. Serum and fecal metabolomics will be investigated.

NCT ID: NCT04704063 Completed - NAFLD Clinical Trials

Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)

T3-NAFL
Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Palm-derived tocotrienols have shown hepatoprotective effects in both animal and human studies. This study aims to investigate the effects of tocotrienols in hepatocellular lipid content using MRI. Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from simple fatty liver (steatosis, NAFL) to non-alcoholic steatohepatitis (NASH) to cirrhosis. NASH is the accumulation of fat in liver cells accompanied with inflammation that can lead to the scarring of the liver. Prevention of liver fibrosis by early introduction of low risk interventions such as lifestyle modification, diet control and nutraceuticals may help circumvent long-term healthcare costs associated with management of chronic NASH.

NCT ID: NCT04226014 Completed - Obesity Clinical Trials

Observational Cohort of Pancreatic Echo-endoscopy

OBELIX
Start date: July 17, 2018
Phase:
Study type: Observational

Metabolic syndrome is defined by the presence of at least two of the following five criteria: abdominal perimeter> 94 cm in men, 80 cm in women, high triglycerides, low HDL cholesterol, HTA and hyperglycemia. The metabolic syndrome can lead to ultrasound hepatic steatosis in 20 to 40% of cases depending on the population studied (overweight vs obesity). What is the impact of this syndrome on pancreatic echogenicity?

NCT ID: NCT04180631 Completed - Hepatic Steatosis Clinical Trials

Quantitative US for Hepatic Steatosis

Start date: March 5, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the diagnostic performance of quantitative ultrasound imaging parameter for the assessment of hepatic steatosis in patients with non-alcoholic fatty liver disease using magnetic resonance imaging proton density fat fraction (MRI-PDFF) and MR spectroscopy as the reference standard.

NCT ID: NCT04081571 Recruiting - Insulin Resistance Clinical Trials

Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian

Start date: April 1, 2019
Phase:
Study type: Observational

Getting a rough indicator about the prevalence of different grade of severity of NAFLD (NASH & liver fibrosis), and Correlate the severity of fatty liver with different serological risk factors of metabolic syndrome and diseases progression as well as the prevalence of hepatocellular carcinoma related to NAFLD with the use of ; nutritional assessment designed and conducted by the investigators in this research, simple blood test (lipid profile and blood sugar), and easy cheap non-invasive radiological tool as screening to predict NASH.

NCT ID: NCT03994029 Recruiting - Obesity, Childhood Clinical Trials

Effect of Polyphenol Supplementation on Hepatic Steatosis and Vascular Compliance

Start date: July 4, 2021
Phase: N/A
Study type: Interventional

The main objective is to study the effect of polyphenol supplementation on hepatic steatosis as measured by hepatic ultrasound, hepatic magnetic resonance imaging and on intima-media thickness and vascular elastography in obese adolescents known for hepatic steatosis as diagnosed by liver biopsy

NCT ID: NCT03961516 Completed - Cystic Fibrosis Clinical Trials

Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis

CFCGM
Start date: May 1, 2019
Phase:
Study type: Observational

The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently sampled oral glucose tolerance test.

NCT ID: NCT03717935 Completed - Obesity Clinical Trials

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

ORANGE
Start date: October 8, 2018
Phase: N/A
Study type: Interventional

The Investigators will measure hepatic glucose and fat metabolism in obese girls with Polycystic Ovarian Syndrome (PCOS) and hepatic steatosis (HS) after taking 4 weeks of an essential amino acid (EAA) supplement or placebo and test whether the EAA supplement can improve hepatic glucose metabolism in these girls.

NCT ID: NCT03587727 Active, not recruiting - Obesity Clinical Trials

Hepatic Mitochondrial Function in Youth

MANGO
Start date: November 20, 2018
Phase:
Study type: Observational

Assess the impact of bariatric surgery on hepatic energy metabolism and glucose and insulin dynamics in obese youth